Simulations Plus has entered a definitive agreement to be purchased by affiliates of Altaris in an all-cash transaction valued at approximately $375m.
Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026
The company’s board of directors unanimously approved the acquisition, which remains subject to customary closing conditions, including shareholder and regulatory approvals. Completion of the transaction is expected in the fourth quarter of 2026. Altaris plans to combine Simulations Plus with Chemical Computing Group (CCG), a company in its portfolio.
CCG provides advanced molecular design software for clients in the pharmaceutical, chemical and materials sectors. The combination aims to build a more comprehensive biosimulation platform for drug discovery and development, supporting customers throughout the entire research and development life cycle. Following the closing of the acquisition, Simulations Plus is expected to become a privately held subsidiary of Altaris.